chronic myeloid leukaemia
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Novartis breaks ground on US radioligand therapy site
The construction is part of the company’s investment in US research and manufacturing
FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders
The mortality rates of UCDs exceeds 25%, with no curative treatment available for newborns
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases